• July 21, 2024

CellCentric gives hope to last-line multiple myeloma patients

UK-based biotech, CellCentric which spun out of Cambridge University has yesterday (December 11) announced new clinical data for the drug at the American Society for Hematology (ASH) in San Diego.

The results follow a recent publication in the Cancer Cell journal, which describes the novel mechanism of action of inobrodib, a first in a new class of drug – an oral agent.  The drug disrupts the action of p300/CBP at regulatory elements controlling key cancer genes.

Inobrodib impacts the expression of IRF4 and MYC, two potent oncogenes that drive multiple myeloma. The mechanism is clearly differentiated from that of other commonly used drugs, and it has also been proven to be synergistic to agents such as the IMiDs.  As now shown clinically, patients refractory to pomalidomide become responsive to inobrodib combined with pom + dex.

“We are pleased that clinical activity of this combination is so encouraging in last-line patients, confirming the potential of this new approach,” said Tomasz Knurowski, chief medical officer at CellCentric.

“Further evaluation is underway, but there are clear signs that targeting p300/CBP to treat haematological malignancies, including myeloma, has the potential to address unmet medical need.”

The data has been derived from heavily pre-treated patients, who are mostly triple-class refractory (when the disease does not respond to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies), with a median of five lines of prior therapy who have been taking part in a multi-center phase 1/2a clinical​ trial.  

Leave a Reply

Your email address will not be published. Required fields are marked *